Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
National Medical Research Center for Cardiology, Ministry of Health of Russian Federation
Age
18–60
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Confirmed diagnosis of PAH II or III functional class according to WHO classification
Symptomatic PAH group 1 according to clinical classification
Patients who have not previously received any PAH-specific therapy OR patients who have received endothelin receptor antagonists and/or iloprost/selexipag at stable doses for at least 3 months prior to the initial right heart catheterization.
Ability to perform reproducible 6-min walking test at the screening with a distance from 150 to 450 m.
You may not be if
as per the study protocol
Clareo Health | Evaluation of the Efficacy and Safety of Oxacom® in Patients With Pulmonary Arterial Hypertension
